ARTHROFLEX PLUS TABLETS (Each tablet contains Glucosamine 500mg/ Chondroitin 400mg/ Methyl Sulfonyl Methane 250mg/ Collagen type 2 40mg/ Hyaluronic Acid 3.3mg)

Indications

• Symptomatic relief of mild to moderate osteoarthritis of the knee

Dosage

Children: Refer to the BNF for Children for

Adults: 200–400 mg daily, maximum 6.5 mg/kg per day, or 1250 mg once daily, or 1500 mg once daily dissolved in at least 250 mL of water; review treatment if no benefit after 2–3 months.

Mechanism of action

The mechanism of action of glucosamine in joint health is not entirely clear, but it is believed to involve several pathways. Glucosamine is a precursor for glycosaminoglycans, which are essential for cartilage integrity. It may also reduce inflammation by inhibiting interferon gamma and Nuclear factor kappa B subunit 65 (NF-κB p65), which could improve symptoms of arthritis and joint pain. Upon uptake by living cells, glucosamine reacts with ATP to form glucosamine-6-phosphate, further contributing to glycosaminoglycan synthesis.

Pharmacodynamics

Glucosamine is theorized to provide essential building blocks for the synthesis of glycosaminoglycans, potentially slowing the progression of osteoarthritis and alleviating joint pain. Although some studies have indicated modest improvements in joint pain and function among users, the overall evidence remains inconclusive. Glycosaminoglycans are critical for maintaining cartilage elasticity, strength, and flexibility, which are vital for joint health.

Pharmacokinetics

After oral administration, glucosamine is absorbed in the gastrointestinal tract and transported into the bloodstream, where it is metabolized into various forms, including glucosamine-6-phosphate. The exact pharmacokinetics, such as absorption rate and half-life, remain largely undefined, and much of the data is derived from animal studies. Further research is required to clarify its pharmacokinetic profiles in humans.

Adverse effects

• Constipation
• Diarrhoea
• Fatigue
• Gastrointestinal discomfort
• Headache
• Nausea
• Flushing
• Skin reactions

Interactions

• Glucosamine + warfarin: Severe (increases anticoagulant effect)
• Glucosamine + coumarins: Severe (increases anticoagulant effect)
• Glucosamine + acenocoumarol: Unknown (decreases anticoagulant effect)
• Glucosamine + coumarins: Unknown (decreases anticoagulant effect)

Precautions

• Asthma
• Impaired glucose tolerance
• Predisposition to cardiovascular disease

Pregnancy

Safety during pregnancy has not been established; consult with a healthcare provider.

Breast-feeding

Safety during breastfeeding has not been established; consult with a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Alateris®
• Dolenio®
• Glusartel®

Indications

• Osteoarthritis
• Joint pain
• Cartilage repair
• Joint health maintenance

Dosage

Children: Refer to healthcare professionals for guidance on dosing in children, as specific pediatric dosing information is not well established.

Adults: Refer to specific product labeling and consult healthcare professionals for guidance on dosing, as dosages can vary based on formulations and clinical guidelines.

Mechanism of action

Chondroitin works primarily by providing the building blocks necessary for the synthesis of glycosaminoglycans, which are critical components of cartilage. It is thought to inhibit the enzymes that break down cartilage, thereby promoting cartilage repair while also exhibiting anti-inflammatory properties. Additionally, chondroitin may enhance the retention of water in the cartilage, improving its elasticity and resilience.

Pharmacodynamics

Chondroitin has been shown to modulate inflammatory responses within the joints and may help to improve joint mobility and reduce pain associated with osteoarthritis. Its effects on cartilage metabolism are believed to contribute to its therapeutic benefits, although the clinical efficacy may vary among individuals. The anti-inflammatory properties may also contribute to a reduction in joint swelling and discomfort.

Pharmacokinetics

Chondroitin is poorly absorbed from the gastrointestinal tract, with bioavailability ranging from 12% to 36%. It is distributed in the extracellular matrix of cartilage and other connective tissues. Metabolism of chondroitin is not well understood, but it is believed to be metabolized in the liver. The elimination half-life in humans is not well defined, and it is primarily excreted via urine as metabolites. The effects of food on its absorption are still under investigation.

Adverse effects

• Nausea
• Diarrhea
• Constipation
• Abdominal pain
• Headache
• Skin reactions

Interactions

• Anticoagulants (e.g., warfarin) - may increase the risk of bleeding
• NSAIDs - may affect the efficacy of these medications

Precautions

• Use with caution in patients with a history of bleeding disorders
• Caution is advised in patients undergoing surgery due to potential bleeding risk
• Patients with shellfish allergies should consult a physician as some chondroitin supplements are derived from marine sources

Pregnancy

There is insufficient reliable information regarding the safety of chondroitin during pregnancy. It is advisable to avoid use unless prescribed by a healthcare professional.

Breast-feeding

It is not known if chondroitin is excreted in human milk. Caution is advised for nursing mothers considering its use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Capsule
• Tablet
• Powder
• Liquid

Indications

• Skin aging and wrinkle reduction
• Joint pain and osteoarthritis
• Tendon and ligament injuries
• Bone health
• Wound healing

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing based on the indication and formulation used.

Adults: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing based on the indication and formulation used.

Mechanism of action

Collagen exerts its effects primarily by providing the necessary amino acids, such as glycine, proline, and hydroxyproline, that are crucial for the synthesis of new collagen in the body. It is thought to stimulate fibroblast proliferation, which leads to increased collagen production and improved tissue repair. Additionally, collagen may enhance the hydration of the skin and improve its elasticity.

Pharmacodynamics

Collagen supplementation may promote the synthesis of new collagen and improve the integrity of the extracellular matrix. This can lead to improved skin hydration, elasticity, and the reduction of wrinkles. In joint health, collagen may help reduce inflammation and pain, contributing to improved mobility and function. The effects can vary based on the source of collagen (bovine, porcine, marine) and the form of administration (powder, liquid, capsules).

Pharmacokinetics

After oral administration, collagen peptides are absorbed in the gastrointestinal tract and enter the bloodstream. They can be transported to various tissues where they may be incorporated into the extracellular matrix. The half-life of collagen peptides is relatively short, and they are metabolized in the liver and other tissues. The bioavailability of collagen can vary based on the formulation and the presence of other dietary components.

Adverse effects

• Allergic reactions
• Skin rash
• Itching
• Gastrointestinal disturbances
• Nausea

Precautions

• Use with caution in individuals with fish allergies if derived from fish sources
• Monitor for allergic reactions

Pregnancy

Collagen is generally considered safe during pregnancy, but consult a healthcare professional before use.

Breast-feeding

Collagen is likely safe during breastfeeding, but consult a healthcare professional before use.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Powder
• Capsules
• Liquid

Indications

• Osteoarthritis
• Dermal filler for aesthetic procedures
• Dry eye syndrome
• Surgical adjunct in ophthalmic procedures

Dosage

Children: Refer to specific product guidelines for dosing, as it varies by formulation and indication.

Adults: Refer to specific product guidelines for dosing, as it varies by formulation and indication.

Mechanism of action

Hyaluronic acid exerts its effects primarily through its ability to bind and retain water, thus contributing to tissue hydration and lubrication. In joints, it provides viscoelastic properties to synovial fluid, reducing friction and facilitating smooth movement. In dermal applications, it promotes skin moisture and elasticity by attracting water to the skin surface.

Pharmacodynamics

The pharmacodynamic properties of hyaluronic acid are attributed to its capacity to form a gel-like structure upon hydration, which enhances its mechanical and biological functions. In joint injections, it alleviates pain and improves function in patients with osteoarthritis by restoring the viscosity of synovial fluid. In cosmetic applications, its hydrophilic nature increases skin volume and smoothness, reducing the appearance of wrinkles.

Pharmacokinetics

Hyaluronic acid is administered via various routes, including intra-articular injections, topical formulations, and subdermal injections. After administration, it is distributed in the extracellular matrix, where it remains for varying durations depending on the formulation and site of application. The half-life can range from hours to days; however, once in the body, it is metabolized by hyaluronidases and other enzymes, with catabolites excreted primarily through urine.

Adverse effects

• Injection site reactions
• Allergic reactions
• Headache
• Dizziness

Precautions

• Use with caution in patients with a history of hypersensitivity to hyaluronic acid or any of its components
• Consider potential risks in patients with bleeding disorders or those on anticoagulant therapy

Pregnancy

Hyaluronic acid is generally considered safe for topical use during pregnancy, but systemic safety has not been fully established. Consult a healthcare provider before use.

Breast-feeding

Topical hyaluronic acid is considered safe for use during breastfeeding, but consult a healthcare provider for systemic use.

Storage

Store at room temperature, away from direct sunlight. Once opened, use as directed and do not freeze.

Formulations

• Injectable solutions
• Topical gels
• Ophthalmic solutions

Dosage

Children: As with adult dosing, methane is not used therapeutically in paediatrics, and thus no specific paediatric doses are provided. Refer to clinical guidelines for any relevant applications.

Adults: Methane is not typically administered as a drug in therapeutic contexts. Therefore, specific dosage recommendations for adults do not apply. Consult relevant guidelines or literature for any potential applications.

Mechanism of action

Methane serves as a carbon source in various metabolic processes, particularly in methanogenic archaea and certain bacteria. It participates in biochemical pathways such as methylphosphonate degradation and the oxidation of methane to methanol, facilitating energy production and carbon cycling in anaerobic environments.

Pharmacodynamics

In the context of environmental and biological systems, methane acts as a substrate for methanogenic organisms. These organisms utilize methane to produce energy through anaerobic respiration. The dynamics of methane in the environment are influenced by factors such as temperature, pH, and the presence of other substrates or microorganisms.

Pharmacokinetics

Methane is generally not absorbed in a conventional pharmacokinetic sense as it is primarily a gas. Its distribution and metabolism occur in the environment rather than within a biological system. Methane's clearance from the atmosphere occurs through various processes, including oxidation to carbon dioxide and assimilation by methanotrophic bacteria.

Pregnancy

Methane is not recommended during pregnancy due to potential risks associated with exposure to flammable gases.

Breast-feeding

There is limited information regarding the effects of methane during breastfeeding, exercise caution.

Storage

Store in a cool, dry place away from sources of ignition and incompatible materials.

Indications

• Allergic conditions
• Autoimmune diseases
• Asthma and chronic obstructive pulmonary disease (COPD)
• Certain cancers (e.g., leukemia, lymphoma)
• Skin conditions (e.g., dermatitis)
• Inflammatory bowel disease
• Multiple sclerosis exacerbations
• Severe infections requiring immunosuppression

Dosage

Children: Refer to BNF for Children for specific dosing; doses vary significantly based on the child's age, weight, and condition being treated.

Adults: Refer to BNF for specific dosing; typically, initial doses range from 4 to 48 mg depending on the severity of the condition.

Mechanism of action

Methylprednisolone exerts its effects by binding to glucocorticoid receptors, leading to the modulation of gene expression. This interaction influences the transcription of anti-inflammatory proteins while suppressing the expression of pro-inflammatory genes, ultimately resulting in reduced inflammation and immune response.

Pharmacodynamics

The pharmacodynamic effects of methylprednisolone are characterized by its ability to decrease inflammation, suppress the immune response, and affect carbohydrate metabolism. Therapeutic doses lead to various systemic effects, including modification of leukocyte distribution and inhibition of cytokine production.

Pharmacokinetics

Methylprednisolone is well absorbed after oral administration, with a bioavailability of approximately 50%. It has a volume of distribution that reflects extensive tissue binding. The drug is metabolized primarily in the liver through conjugation and reduction, and its metabolites are excreted in urine. The half-life varies based on the route of administration but is generally around 18 to 36 hours.

Adverse effects

• Increased blood pressure
• Hyperglycemia
• Weight gain
• Mood changes
• Insomnia
• Gastrointestinal disturbances
• Increased susceptibility to infections

Interactions

• methylphenidate+apraclonidine: Severe (decreases effects)
• methylthioninium chloride+bupropion: Severe (increases risk of severe hypertension)
• methylphenidate+linezolid: Severe (increases risk of elevated blood pressure)
• rasagiline+methylphenidate: Severe (increases risk of a hypertensive crisis)
• mao-inhibitors+methylphenidate: Severe (increases risk of a hypertensive crisis)
• dronedarone+methylprednisolone: Moderate (increases exposure)
• miconazole+methylprednisolone: Moderate (increases concentration)
• antifungals, azoles+methylprednisolone: Moderate (increases exposure)
• crizotinib+methylprednisolone: Moderate (increases exposure)

Precautions

• Use with caution in patients with hypertension
• Monitor blood glucose levels in diabetic patients
• Consider potential for infection risk due to immunosuppression
• Evaluate for psychiatric effects in susceptible individuals

Pregnancy

Corticosteroids may be used during pregnancy if the potential benefit justifies the risk to the fetus. Careful monitoring is advised.

Breast-feeding

Corticosteroids are excreted in breast milk; caution is advised. Monitor the infant for potential effects.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Tablets
• Injectable solutions
• Topical preparations

Mechanism of action

Methylsulphate functions as a methylating agent, transferring a methyl group to nucleophiles. This process involves the formation of a sulfonium ion, which is highly reactive and can readily react with nucleophilic sites on various substrates, leading to methylation reactions.

Pharmacodynamics

The pharmacodynamics of methylsulphate is primarily related to its role as a methylating agent in biochemical reactions. It can alter the structure and function of biological molecules, potentially affecting cellular processes and signaling pathways. However, detailed pharmacodynamic studies specific to therapeutic use are limited.

Pharmacokinetics

There is limited information on the pharmacokinetics of methylsulphate, given its typical use as a reagent in laboratory settings rather than a clinical drug. When used in chemical reactions, its reactivity and transformation into other compounds would dictate its pharmacokinetic profile, which could vary significantly based on the specific context of use.

Pregnancy

There is limited data on the use of methylsulphate in pregnancy. Consult relevant guidelines.

Breast-feeding

Data on the excretion of methylsulphate in human milk is not available. Caution is advised.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Type 2 diabetes mellitus
• Hyperglycemia management

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations for pediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on individual patient needs and the specific sulfonylurea being used.

Mechanism of action

Sulfonylureas, including sulfonyl, act by binding to the sulfonylurea receptor (SUR) on pancreatic beta cells. This interaction closes ATP-sensitive potassium channels, leading to depolarization of the cell membrane. As a result, calcium channels open, causing an influx of calcium ions that trigger insulin secretion. Additionally, sulfonylureas may also enhance the binding of insulin to its receptors in peripheral tissues, thus improving insulin sensitivity.

Pharmacodynamics

The pharmacodynamic effects of sulfonylureas include increased insulin secretion from the pancreas and improved peripheral utilization of glucose. They also exhibit a duration of action that can vary depending on the specific sulfonylurea used, with some having a longer duration than others. The overall effect leads to a decrease in blood glucose levels, which is essential for managing hyperglycemia in diabetic patients.

Pharmacokinetics

Sulfonylureas are generally well-absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. They are highly protein-bound, mainly to albumin, and have variable half-lives depending on the specific drug. Metabolism primarily occurs in the liver, and the metabolites are excreted via the kidneys, necessitating caution in patients with renal impairment.

Interactions

• bosentan+sulfonylureas: Severe (increases risk of hepatotoxicity)
• amiodarone+sulfonylureas: Moderate (increases exposure)
• voriconazole+sulfonylureas: Moderate (increases concentration)
• ceritinib+sulfonylureas: Moderate (increases exposure)
• metreleptin+sulfonylureas: Moderate (increases risk of hypoglycaemia)
• roxadustat+sulfonylureas: Moderate (increases exposure)
• darolutamide+sulfonylureas: Unknown (increases concentration)
• bulevirtide+sulfonylureas: Unknown (increases exposure)
• ceftobiprole+sulfonylureas: Unknown (increases concentration)
• chloramphenicol+sulfonylureas: Unknown (increases exposure)

Pregnancy

Sulfonylureas may be used with caution in pregnancy. However, they should only be prescribed if the potential benefit outweighs the risk. Glycemic control is essential during pregnancy.

Breast-feeding

Sulfonylureas are generally not recommended during breastfeeding due to the potential risk of hypoglycaemia in the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Mechanism of action

The mechanism of action of glucosamine in joint health is unclear, however there are several possible mechanisms that contribute to its therapeutic effects. Because glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage, glucosamine supplements may help to rebuild cartilage and treat the symptoms of arthritis. Some in vitro studies show evidence that glucosamine reduces inflammation via inhibition of interferon gamma and Nuclear factor kappa B subunit 65 (NF-κB p65), improving the symptoms of arthritis and joint pain. Clinical relevance is unknown at this time. When taken up by living cells, glucosamine reacts with ATP to form glucosamine-6-phosphate, the natural precursor of glycosaminoglycans (GAGs) that contain N-acetylglucosamine (keratan sulfate and Hyaluronan) and those that have N-acetylgalactosamine (heparan sulfate and chondroitin sulfate). These GAGs are polysaccharides composed of hexosamines and monosaccharides (e.g., galactose and glucuronic acid) arranged as a linear chain of repeating disaccharide units (such as the glucuronic acid and N-acetylgalactosamine-6-sulfate of chondroitin sulfate). With the exception of hyaluronan, GAGs do not exist alone in nature but are attached to specific "core" proteins, and the composite structures are called proteoglycans (protein-glycosaminoglycans). Both hyaluronan and many different kinds of proteoglycans (such as aggrecan, versican, and syndecan) are abundant throughout the body where they perform diverse functions.

Pharmacodynamics

The administration of glucosamine, in theory, provides a building block towards the synthesis of glycosaminoglycans, slowing the progression of osteoarthritis and relieving symptoms of joint pain. Studies to this date examining the efficacy of glucosamine sulfate have been inconclusive. Glycosaminoglycans contribute to joint cartilage elasticity, strength, and flexibility. A systematic review of various studies and guidelines determined that modest improvements were reported for joint pain and function in patients taking glucosamine. A consistent joint space narrowing was observed, but with an unclear clinical significance.